BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...

Aston Villa’s perfect run meets Barcelona’s Camp Nou jinx
Djokovic turns Vacherot scare into a 319-point chase at Paris Masters
Pension measures move on multiple fronts as Eighth Pay Commission clocks one year
India Left Without Rooms in Dhaka as SAFF Championship Begins with Pakistan Clash
Hero Xpulse 450 Debuts at EICMA 2026 With 421cc Engine and Apple CarPlay 
















